Stock comparison
Eli Lilly
Neurocrine Biosciences
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LLY
Eli Lilly
Market cap
$1T
Sector
Healthcare
NBIX
Neurocrine Biosciences
Market cap
$15.76B
Sector
Healthcare
Overall winner
Eli Lilly LLY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LLY | NBIX | Winner |
|---|---|---|---|
| Warren Buffett | 72B | 68B | LLY |
| Benjamin Graham | 86A | 78B | LLY |
| Philip Fisher | 86A | 80A | LLY |
| Peter Lynch | 74B | 65B | LLY |
| Joel Greenblatt | 78C | 55C | LLY |
| Charlie Munger | 85A | 60C | LLY |
| Terry Smith | 77C | 63D | LLY |
Side-by-side metrics
| Metric | LLY | NBIX |
|---|---|---|
| Market cap | $1T | $15.76B |
| P/E (TTM) | 36.6x | 22.6x |
| EV/EBIT | 34.1x | 24.7x |
| ROIC (TTM) | 32.06% | 13.68% |
| Gross margin | 83.51% | 98.17% |
| Net margin | 34.98% | 21.55% |
| Revenue CAGR 5y | 23.17% | 26.04% |
| EPS CAGR 5y | 40.81% | 50.0% |
| Debt / Equity | 1.4x | 0.1x |
| Dividend yield | 0.62% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LLY leads on
- Dividend yield0.62%vs 0.0%+100%
- Market cap$1Tvs $15.76B+98%
- ROIC (TTM)32.06%vs 13.68%+57%
- Net margin34.98%vs 21.55%+38%
NBIX leads on
- Debt / Equity0.1xvs 1.4x+91%
- P/E (TTM)22.6xvs 36.6x+38%
- EV/EBIT24.7xvs 34.1x+28%
- EPS CAGR 5y50.0%vs 40.81%+18%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.